Korea Drills Its Drugmakers on Global GMP as Export Ambitions Grow

South Korea’s push to turn its pharmaceutical industry into a serious export force is increasingly running through the classroom. Dongguk University’s Pharmaceutical Training Institute staged two GMP-focused training events on consecutive days in Seoul — an international seminar on continuous manufacturing, process analytical technology (PAT) and digital manufacturing platforms on the 20th, followed by a course on data integrity and data-governance-based smart quality management on the 21st — both organized under a Ministry of Food and Drug Safety research program that exists for one stated purpose: strengthening the global competitiveness of Korean drugmakers seeking to expand overseas.

Two Days, Two Layers of the Same Problem

The pairing of topics is telling. The first event, billed as the 2026 first Pharmaceutical Innovation Technology GMP International Seminar and held at the Ambassador Seoul Pullman hotel, dealt with the production side of modern pharmaceutical manufacturing — continuous processing, PAT and digital manufacturing platforms, the technologies that major regulators increasingly expect to see in facilities supplying advanced markets.

The second, held at Hyehwa Hall on Dongguk University’s Seoul campus, was the fourth installment in the institute’s Global GMP-based pharmaceutical innovation capacity-building series and addressed the compliance side: data integrity and smart manufacturing quality management built on data governance. Data integrity has become one of the most common grounds for inspection findings when manufacturers face scrutiny from foreign regulators, which makes it a practical bottleneck for any company whose business plan depends on approvals outside Korea.

Together the two programs sketch the full journey an export-oriented manufacturer has to make: modernize the plant, then prove — with trustworthy records — that the modernized plant is under control.

The Regulator Behind the Curriculum

That the funding comes from the Ministry of Food and Drug Safety fits a longer institutional arc. The regulator was elevated from an administration to a full ministry in March 2013, and it participates as a regulatory member of the International Council for Harmonisation, the body that coordinates pharmaceutical technical requirements across major markets. Membership in that club cuts both ways: it gives Korean approvals more international standing, but it also binds Korean manufacturers to the same technical expectations their competitors in the United States, Europe and Japan face.

Underwriting university-run GMP education is a low-cost way for the ministry to close the gap between those expectations and current industry practice — particularly for small and mid-sized firms that cannot maintain in-house regulatory science teams the way the largest Korean pharmaceutical groups can.

Why Training Is the Cheap Part of Market Entry

For companies eyeing foreign markets, the economics are straightforward. A failed inspection or a data-integrity finding at a foreign regulator’s audit can delay a product launch by years; a seminar series costs almost nothing by comparison. The curriculum choices — continuous manufacturing and PAT one day, data governance the next — suggest the program is aimed less at introducing novel science than at making sure Korean production sites can withstand the kind of scrutiny that comes with selling into strictly regulated markets.

The open question is scale. A seminar series can raise awareness across an industry, but converting that awareness into inspection-ready facilities requires capital investment and sustained management attention that no training program can substitute for. What the ministry’s sponsorship signals most clearly is that Korea’s regulator sees manufacturing quality — not just clinical innovation — as the gating factor for the industry’s next phase of growth abroad.